Glaxo Seeks Approval for World’s First Malaria Vaccine
This article is for subscribers only.
GlaxoSmithKline Plc applied for regulatory approval of its experimental malaria vaccine, bringing it closer to becoming the first shot against the world’s deadliest mosquito-borne disease.
Glaxo is seeking approval to sell its RTS,S vaccine exclusively outside the European Union, London-based Glaxo said in a statement today. The request is part of a process in which the European Medicines Agency can assess a product made in an EU member state against a disease recognized by the World Health Organization as a major public health interest, for use in the rest of the world.